Healthcare: How Marijuana Legalization Impacted OrganiGram and Aphria's Latest Results

Marijuana stocks OrganiGram and Aphria reported quarterly earnings this week - here's what you should know. Also, Abbott locks horns with DexCom in diabetes and what's next for Bristol-Myers' now that its Celgene acquisition is official. Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter